创新药“中国首发”密集落地 新靶点、新机制、新疗法加速向中国集聚

格隆汇
Aug 11
近期,一款罕见病创新药在中国“首报首发”,引起广泛关注。这并非孤例——今年以来,已有多款跨国药企的创新药在中国率先上市,与此同时,百利天恒、科济药业等本土企业的全球首创新药也密集落地。跨国巨头与本土企业不约而同地将首发地设在中国,延续数十年的“先欧美、后中国”旧格局,被彻底改写。“中国首发”成为常态,创新药正以黑马之姿跻身我国“新新三样”的行列。这场首发潮的背后,是新靶点、新机制、新疗法加速向中国集聚,中国创新药产业正从全球参与者迈向全球引领者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10